Skip to main content

Generics

  • Perrigo launches generic Axiron

    DUBLIN — Perrigo on Wednesday announced the introduction of its generic of Axiron (testosterone, 30 mg/1.5 ml) topical solution. The drug is indicated for replacement therapy in males with an endogenous testosterone deficiency or absence.

  • Endo to divest Mexican generics arm Grupo Farmcéutico SOMAR

    DUBLIN — Endo will be selling its Mexico City-based Grupo Farmcéuitco SOMAR division to Advent International, the company announced Wednesday. The deal will see the Mexican private generics leader sold to Advent for roughly $124 million.

  • Sandoz inks deal with Vectura to develop inhaled asthma, COPD generic

    CHIPPENHAM, U.K. — Vectura Group is looking to Novartis’ Sandoz division to bring a generic inhaled asthma and COPD treatment to the United States. The company on Wednesday announced the agreement, which will see Sandoz developing and commercializing a generic of a major inhaled combination therapy delivered using a pressurized metered dose inhaler.

  • Lupin launches 2 Topicort generics

    MUMBAI and BALTIMORE — Lupin recently introduced its generic of Taro’s Topicort LP Emollient Cream and Topicort Cream (desoximetasone cream 0.05% and desoximetasone cream 0.25%). The treatments are indicated for the relief of corticosteroid-responsive dermatoses.

    The company said that the creams had combined U.S. sales of $38 million for the 12 months ended Aril 2017, according to QuintilesIMS data.

     

  • Natco Pharma gets FDA approval for generic Vidaza
    SILVER SPRING, Md. — The Food and Drug Administration has approved Natco Pharma’s generic of Celgene and Breckenridge’s Vidaza (azacitidine for injection). The drug is indicated to treat myelodysplastic syndrome.
     
    Natco’s generic will be available in a dosage strength of 100 mg per vial. The drug had combined sales of $188 million for the 12 months ended April 2017, the company said.
     

  • Blink Health commits $10M to give patients year's supply of common diabetes meds

    NEW YORK —Blink Health has announced an effort to bring $10 million worth of free Type 2 diabetes medications to patients using the prescription drug savings platform.

    Patients with diabetes who create an account on the Blink Health website or mobile app will be able to receive a year’s supply of metformin, glipizide and pioglitazone for free. The progam also will cover existing Blink Health users who take these medications, the company said.

  • FDA takes first steps in Drug Competition Action Plan for generics

    SILVER SPRING, Md. — The Food and Drug Administration has taken the first step in its recently announced effort to bring more generics to market to increase competition. The agency has posted a list of branded drugs that have no listed patents or exclusivities that currently have no approved generics and has instituted a new policy to speed up review of applications for generics of products with limited competition.

  • Teva introduces generic Trilafon

    NORTH WALES, Penn. — Teva has launched its generic of Trilafon (perphenazine) tablets. The drug is indicated to treat schizophrenia and to control severe nausea and vomiting in adults.

    “Our customers count on Teva for a continuous supply of new generic products,” Teva COO North American generics Maureen Cavanaugh said. “With the launch of perphenazine tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”

    Teva’s generic is available in 2-, 4-, 8- and 16-mg dosage strengths.
     

X
This ad will auto-close in 10 seconds